ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Merck In Heart Drug Deal With ElexoPharm

by Lisa M. Jarvis
May 24, 2010 | APPEARED IN VOLUME 88, ISSUE 21

Merck & Co. and German contract research organization ElexoPharm will work together to develop novel drug candidates targeting aldosterone synthase for the treatment of cardiovascular disease. Elexo­Pharm scores $1.9 million up front and could receive another $40 million in milestones throughout the course of the pact. ElexoPharm was spun out of Saarland University’s department of pharmaceutical and medicinal chemistry in 2005.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment